Research map: Temporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translation

Back to the article

Papers in this map

  1. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion · Robert D. Schreiber · 2011 · 6575 citations · Cited by this paper
  2. Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · 2026 · Related
  3. Epigenetic memory in induced pluripotent stem cells · K. Kim · 2010 · 2329 citations · Cited by this paper
  4. Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · 2026 · Related
  5. Immunogenicity of induced pluripotent stem cells · Tongbiao Zhao · 2011 · 1451 citations · Cited by this paper
  6. Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study · 2026 · Related
  7. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway · Hyenjong Hong · 2009 · 1315 citations · Cited by this paper
  8. Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · 2026 · Related
  9. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation · Stephanie J. Lee · 2007 · 1266 citations · Cited by this paper
  10. Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · 2026 · Related
  11. Copy number variation and selection during reprogramming to pluripotency · Samer M. I. Hussein · 2011 · 963 citations · Cited by this paper
  12. Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · 2026 · Related
  13. Dynamic Changes in the Copy Number of Pluripotency and Cell Proliferation Genes in Human ESCs and iPSCs during Reprogramming and Time in Culture · Louise Chang Laurent · 2011 · 906 citations · Cited by this paper
  14. The role of monoclonal antibodies in the treatment of lupus nephritis · 2026 · Related
  15. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients · T. Deuse · 2019 · 775 citations · Cited by this paper
  16. Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · 2026 · Related
  17. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies · Andrew S. Lee · 2013 · 738 citations · Cited by this paper
  18. Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · 2026 · Related
  19. Mismatches of Minor Histocompatibility Antigens between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease after Bone Marrow Transplantation · Els Goulmy · 1996 · 611 citations · Cited by this paper
  20. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage · The International Stem Cell Initiative · 2011 · 603 citations · Cited by this paper
  21. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations · Florian T. Merkle · 2017 · 536 citations · Cited by this paper
  22. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells · Ryoko Araki · 2013 · 509 citations · Cited by this paper
  23. Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types · Craig J. Taylor · 2012 · 434 citations · Cited by this paper
  24. HLA-haplotype banking and iPS cells · Norio Nakatsuji · 2008 · 345 citations · Cited by this paper
  25. Toward the Development of a Global Induced Pluripotent Stem Cell Library · Marc Turner · 2013 · 245 citations · Cited by this paper
  26. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines · George Q. Daley · 2016 · 228 citations · Cited by this paper
  27. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease · Nobukatsu Sawamoto · 2025 · 192 citations · Cited by this paper
  28. Minor histocompatibility antigens: past, present, and future · Eric Spierings · 2014 · 101 citations · Cited by this paper
  29. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells · Ralf Dressel · 2011 · 57 citations · Cited by this paper
  30. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update · Agnete Kirkeby · 2025 · 33 citations · Cited by this paper
  31. Stem the tide · 2015 · 24 citations · Cited by this paper
  32. Possible NK cell-mediated immune responses against iPSC-derived cells in allogeneic transplantation settings · Kyoko Masuda · 2021 · 19 citations · Cited by this paper
  33. Too little, too soon: Japan’s experiment in regenerative medicine deregulation · David Cyranoski · 2023 · 9 citations · Cited by this paper
  34. First-of-a-kind stem-cell therapies set for approval in Japan · Asher Mullard · 2026 · 6 citations · Cited by this paper
  35. p53 safeguards chemical reprogramming of human somatic cells toward pluripotency · Lin Na Cheng · 2026 · 5 citations · Cited by this paper
  36. Dark Clouds Looming Over Regenerative Medicine in Japan · Hiroshi Kawaguchi · 2025 · 4 citations · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)